Warning: count(): Parameter must be an array or an object that implements Countable in /home/hmc/public_html/wp-content/plugins/formcraft3/formcraft-main.php on line 1013
Welcome to Anticoagulant Symposium Post Activity Assessment
Thank you and congratulations for attending this educational activity. Remember, continuous professional development is key to success and professional excellence.
This test is composed of 27 questions based on the information provided to you during the activity. You will have two attempts to complete this test. The 30 minutes which will allow enough time to search for the correct answers.
You must exceed the passing score (60%) in order to receive your certificate.
Updates on Anticoagulant
Quiz Summary
0 of 27 questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 27 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- Anticoagulant 0%
- Anticoagulant 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- Current
- Review
- Answered
- Correct
- Incorrect
-
Question 1 of 27
1. Question
A combination of reflux due to valvular incompetence, and venous hypertension due to thrombotic obstruction, is thought to contribute to post-thrombotic syndrom
CorrectIncorrect -
Question 2 of 27
2. Question
The presence of factor V Leiden or prothrombin gene mutation is reportedly an independent predictor of a higher risk of PTS
CorrectIncorrect -
Question 3 of 27
3. Question
The incidence of rate VTE is high in individuals with cancer of
CorrectIncorrect -
Question 4 of 27
4. Question
A recent guideline for antithrombotic therapy does not recommend routine use of ECSs to prevent PTS in patients with acute DVT
CorrectIncorrect -
Question 5 of 27
5. Question
Which of the following factors are found to be significant predictors for the development of VTE
CorrectIncorrect -
Question 6 of 27
6. Question
Among patient with venous leg ulcers, the use of Intermittent Pneumatic Compression with standard wound care was reported significantly promoted wound healing
CorrectIncorrect -
Question 7 of 27
7. Question
Which of the chemotherapeutic agent is not associated with increased risk of venous and arterial thrombosis
CorrectIncorrect -
Question 8 of 27
8. Question
Available evidence suggests that exercise training may improve PTS symptoms
CorrectIncorrect -
Question 9 of 27
9. Question
Enoxaparin is the recommended thromboprophylactic regimens in cancer patients
CorrectIncorrect -
Question 10 of 27
10. Question
The use of DOAC is FDA approved for DVT prophylaxis in acute medically ill patients?
CorrectIncorrect -
Question 11 of 27
11. Question
If the cancer is resolve ,it is recommended to continue anticoagulant as patient has history of thrombosis
CorrectIncorrect -
Question 12 of 27
12. Question
What is the studied dose of DOAC in DVT prophylaxis in acute medically ill patients:
CorrectIncorrect -
Question 13 of 27
13. Question
The initial heparin dose in the non-obese 16 units/kg/h and 12 units/kg/h in the obese and morbidly obese are associated with similar time to first therapeutic aPTT
CorrectIncorrect -
Question 14 of 27
14. Question
what are the benefits of using DOAC in DVT prophylaxis in acute medically ill patients :
CorrectIncorrect -
Question 15 of 27
15. Question
Based on the available clinical data and pharmacokinetic properties of Rivaroxaban , no dose adjustments are required with regard to the patient’s body we
CorrectIncorrect -
Question 16 of 27
16. Question
The extended duration of RIvaroxaban was safe and effective when compared with 10 days enoxaparin .
CorrectIncorrect -
Question 17 of 27
17. Question
Dabigatran may be considered in obese patients
CorrectIncorrect -
Question 18 of 27
18. Question
Clinical scores, in combination with patient clinical examination and laboratory tests improve:
CorrectIncorrect -
Question 19 of 27
19. Question
Apixaban has the best evidence for utilization of DOACs in obese patients.
CorrectIncorrect -
Question 20 of 27
20. Question
Before the score is used in clinical practice the predictive ability of the model should be evaluated. the model is validated internally or externally
CorrectIncorrect -
Question 21 of 27
21. Question
According to the CDC, the number of elder person that got VTE is 1 to 1000 person
CorrectIncorrect -
Question 22 of 27
22. Question
Which model implies ascribing groups of patients to broad risk categories or “buckets” of risk without going through individualized point scoring
CorrectIncorrect -
Question 23 of 27
23. Question
The use of anticoagulant increased in Artrial fibrillation patient in order to reduces the risk of ischemic stroke
CorrectIncorrect -
Question 24 of 27
24. Question
Khorana risk score is validated to assess the risk of VTE in cancer patients starting chemotherapy
CorrectIncorrect -
Question 25 of 27
25. Question
Dabigatran can help reduce the risk of stroke in AFib not caused by a heart valve problem
CorrectIncorrect -
Question 26 of 27
26. Question
According to chest guide line DOAC are preferred than warfarin on treatment of VTE
CorrectIncorrect -
Question 27 of 27
27. Question
The utility of the NOACs for VTE treatment in vulnerable patients, such as those who are morbidly obese is clear now and established by new studies
CorrectIncorrect